Genome Engineering Market - Increasing development of novel technologies in genome engineering | Thermo Fisher Scientific Inc., CRISPR Therapeutics AG

Coherent Market Insights released a new market study on 2021-2028 Genome Engineering Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. Report offering you more creative solutions that combine our deep geographic experience, intimate sector knowledge and clear insights into how to create value in your business. The research study provides estimates for 2021-2028 Genome Engineering Market Forecast till 2028*.

Request Here For Market Latest Insights(PDF): https://www.coherentmarketinsights.com/insight/request-pdf/1262

Genome engineering is the synthetic assembly of complete chromosomal DNA that is more or less derived from natural genomic sequences. There are two types of gene therapy namely Ex-Vivo Gene Therapy and In-Vivo Gene Therapy. In Ex-vivo gene therapy, genes are transferred into cultured cells and then reintroduced in patient, On the contrary, in In-vivo gene therapy, genes are directly delivered in cells of a particular tissue. Key companies such as CRISPR Therapeutics AG, Editas Medicine, Inc., and Intellia Therapeutics, Inc. are focusing on developing In-Vivo and Ex-vivo gene therapy. Major techniques used in genome engineering are CRISPR, TALEN, and ZFN. CRISPR (CRISPR-Cas9). Moreover, there novel genome editing tools available for researchers to edit parts of the genome by adding, removing, or altering sections of the DNA sequence. In which, CRISPR is an accurate, faster, and cheaper technique for editing DNA as compared to others methods such as TALEN and ZFN. Transcription activator-like effector nucleases (TALEN) is a technology widely used in live cell gene editing. Zinc-finger nucleases (ZFNs) is an artificial restriction enzyme, which simplifies targeted editing of genome by creating double-strand breaks in DNA at user-specified locations.

Market Dynamics- Drivers

Increasing development of novel technologies in genome engineering is expected to drive growth of the global genome engineering market in the near future

Introduction of novel technologies in genome engineering by key market players is expected to drive growth of the global genome engineering market during the forecast period. For instance, in February 2018, Sangamo Therapeutics, Inc. received clinical trial authorization (CTA) from Medicines and Healthcare Products Regulatory Agency (MHRA) in the U.K. for its SB-FIX, a zinc finger nuclease (ZFN)-mediated in-vivo genome editing treatment for hemophilia B. CTA has allowed for the beginning of Europe's first in-vivo genome editing study. In 2017, Integrated DNA Technologies, Inc. launched the first Cas9 enzyme variant, which reduces off-target effects in CRISPR genome editing. The launch of latest Cas9 enzyme variant is a major step towards therapeutic use of CRISPR. In 2017, Scientists at Salk Institute for Biological Studies, modified CRISPR to epigenetically treat diabetes, kidney disease, and muscular dystrophy. They developed a latest version of CRISPR/Cas9 genome editing technology, which allows for activation of genes without creating breaks in the DNA. Therefore, advancement in technologies is expected to propel the global genome engineering market growth over the forecast period.

The global genome engineering market was valued at US$ 2,582.7 Mn in 2016 and is expected to witness a CAGR of 14.3% over the forecast period (2017–2025).

Increasing strategic collaboration for genome engineering technologies by key players is expected to drive market growth in the near future

Key players in the market are involved in various growth strategies such as collaborations, agreement, and partnerships, in order to gain competitive edge in the market. For instance, in February 2018, Kite Pharma, Inc., a Gilead Sciences, Inc. company, entered into collaborative agreement with Sangamo Therapeutics Inc. for developing engineered cell therapies to treat cancer. As per the agreement, Kite Pharma, Inc. will use Sangamo Therapeutics’ zinc finger nuclease (ZFN) gene-editing technology for developing next-generation ex vivo cell therapies for treatment of cancer. Furthermore, in 2017, Synthego and Thermo Fisher Scientific collaborated to manufacture and distribute synthetic guide RNA products for CRISPR genome engineering. In 2016, CRISPR Therapeutics and Bayer AG collaborated and formed a joint venture Casebia Therapeutics, for developing CRISPR-based therapeutics in select disease areas. Moreover, in 2017, Casebia Therapeutics collaborated with CureVac AG. According to collaborative agreement, CureVac will develop novel Cas9 mRNA constructs with improved properties for gene editing applications. In 2015, AstraZeneca plc entered into research collaborations with The Wellcome Trust Sanger Institute, The Innovative Genomics Initiative, Thermo Fisher Scientific, and Broad Institute/Whitehead Institute to use their CRISPR technology for genome editing. Such strategic collaborations among major key players and research institutes is expected to drive market growth in the near future.

Moreover, increasing funding and investments for the development and research of new genetic engineering technologies is also expected to drive market growth. For instance, in January 2018, the U.S. National Institutes of Health (NIH) announced to grant US$ 190 million for genome editing research. This new program, Somatic Cell Genome Editing, will award funds to biomedical researchers over the following six years. The support from major research organizations such as NIH is expected to attract more researchers in this field, which may lead to advancements in technology and also aid in growth of the market.

Market Dynamics- Restraints

High cost associated with genome engineering technologies is expected restrain growth of the global genome engineering market over the forecast period. For instance, according to the fees chart provided by Yale Genome Editing Center, in 2018, it charges between US$ 8,000 and US$ 15,000 for gene editing facilities. The high cost associated with genome engineering facilities is expected to hamper the market growth, especially in emerging economies such as India, Brazil, and South Africa. Moreover, genome engineering is a very complex technology and needs high skilled researchers, which limits its adoption rate.

Genome Engineering Market – Competitive Landscape

Key players functioning in the global prosthetic liners market consists of Thermo Fisher Scientific Inc., CRISPR Therapeutics AG, Intellia Therapeutics, Inc., Editas Medicine, Inc., Sangamo Therapeutics, Inc., Bluebird Bio, Inc., Cellectis S.A., and Merck Group.

Purchase this Report - https://www.coherentmarketinsights.com/insight/buy-now/1262

Reasons to Purchase this Report

• Current and future of global Genome Engineering Market outlook in the developed and emerging markets • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period. • Regions/countries that are expected to witness the fastest growth rates during the forecast period • The latest developments, market shares, and strategies that are employed by the major market players

Major Point Answered in Genome Engineering Market Research Study are:

What will be the progress rate of the Genome Engineering Market for the conjecture period, 2021-2028?
What are the prominent factors driving the Genome Engineering Market across different regions?
Who are the major vendors dominating the Genome Engineering industry and what are their winning strategies?
What will be the market scope for the estimated period?
What are the major trends shaping the expansion of the industry in the coming years?
What are the challenges faced by the Genome Engineering Market?

Request Here Sample Report @ https://www.coherentmarketinsights.com/insight/request-sample/1262

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.